Sumitomo Pharma America, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
Clinical Trials
179
Active:3
Completed:150
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:52
Phase 2:31
+3 more phases
Drug Approvals
9
FDA:7
NMPA:2
Drug Approvals
Lurasidone Hydrochloride Tablets
- Product Name
- 罗舒达
- Approval Number
- 国药准字HJ20190021
- Approval Date
- Aug 10, 2023
NMPA
Lurasidone Hydrochloride Tablets
- Product Name
- 罗舒达
- Approval Number
- 国药准字HJ20191009
- Approval Date
- Aug 10, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (175 trials with phase data)• Click on a phase to view related trials
Phase 3
81 (46.3%)Phase 1
52 (29.7%)Phase 2
31 (17.7%)Phase 4
8 (4.6%)Not Applicable
2 (1.1%)Early Phase 1
1 (0.6%)A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Phase 1
Recruiting
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: DSP-3077 Retinal Sheet Cohort 1Drug: DSP-3077 Retinal Sheet Cohort 2Drug: DSP-3077 Retinal Sheet Cohort 3
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06891885
- Locations
- 🇺🇸
Massachusetts Eye and Ear, Boston, Massachusetts, United States
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
Phase 1
Recruiting
- Conditions
- Parkinson's Disease
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT06753331
- Locations
- 🇺🇸
New York Presbyterian Hospital-Columbia University Medical Center, New York, New York, United States
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States
SMP-3124LP in Adults With Advanced Solid Tumors
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06526819
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
Active, not recruiting
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06517940
- Locations
- 🇺🇸
Mass Eye and Ear, Boston, Massachusetts, United States
Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06389955
- Locations
- 🇺🇸
Frontage Investigative Site, Secaucus, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 36
- Next
News
No news found